Menard Financial Group LLC Acquires 83 Shares of Johnson & Johnson (NYSE:JNJ)

Menard Financial Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,758 shares of the company’s stock after purchasing an additional 83 shares during the quarter. Menard Financial Group LLC’s holdings in Johnson & Johnson were worth $784,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership raised its holdings in Johnson & Johnson by 42.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,004,994 shares of the company’s stock worth $1,479,971,000 after acquiring an additional 2,688,957 shares during the period. Sanders Capital LLC raised its holdings in Johnson & Johnson by 28.1% in the 1st quarter. Sanders Capital LLC now owns 8,441,664 shares of the company’s stock worth $1,543,394,000 after acquiring an additional 1,851,609 shares during the period. BlackRock Inc. raised its holdings in Johnson & Johnson by 0.9% in the 2nd quarter. BlackRock Inc. now owns 191,385,110 shares of the company’s stock worth $31,528,781,000 after acquiring an additional 1,694,112 shares during the period. Canada Pension Plan Investment Board raised its holdings in Johnson & Johnson by 55.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,730,681 shares of the company’s stock worth $777,487,000 after acquiring an additional 1,685,664 shares during the period. Finally, Mn Services Vermogensbeheer B.V. bought a new position in Johnson & Johnson in the 2nd quarter worth $191,090,000. Institutional investors and hedge funds own 67.29% of the company’s stock.

Shares of Johnson & Johnson stock traded up $0.15 during trading on Wednesday, hitting $164.68. 125,687 shares of the company’s stock traded hands, compared to its average volume of 7,125,981. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.39 and a quick ratio of 1.13. The firm’s fifty day moving average price is $171.98 and its 200 day moving average price is $167.47. Johnson & Johnson has a twelve month low of $133.65 and a twelve month high of $179.92. The company has a market cap of $433.52 billion, a PE ratio of 24.74, a PEG ratio of 2.23 and a beta of 0.71.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.19. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The business had revenue of $23.31 billion for the quarter, compared to analyst estimates of $22.54 billion. During the same period in the previous year, the business earned $1.67 EPS. The firm’s revenue was up 27.1% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.65 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Tuesday, August 24th were given a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 52.80%.

Several research analysts recently commented on JNJ shares. Credit Suisse Group set a $193.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Morgan Stanley downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective on the stock. in a report on Tuesday, September 7th. Finally, SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $190.38.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Story: Stocks Increasing Dividends

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.